Senior Director, Patient Safety (MD) (Oncology)

Location: Parsippany, New Jersey, United States

Salary: $255,425–$330,550 per year for other U.S. locations. Bay Area range: $281,010–$363,660 per year.

Company

hirify.global is a biopharmaceutical company developing CAR T-cell and T-cell receptor engineered therapies for cancer immunotherapy.

What you will do

• Provide medical strategy and safety input for regulatory decisions, advisory panels, and stakeholder meetings.
• Lead pharmacovigilance strategy for assigned products or therapeutic areas, including surveillance, aggregate review, and risk management planning.
• Identify and assess safety signals and trends with drug safety risk management teams.
• Lead product-focused safety activities and communicate key findings to senior management.
• Drive process changes, SOP updates, audits, data analysis, and initiatives based on GVP and regulatory guidance.
• Provide strategic input to mitigate pharmacovigilance-related risks.

Requirements

• MD degree or equivalent, board eligible, with 12 years of relevant experience.
• At least 8 years of drug safety, pharmaceutical industry, or clinical practice experience with extensive pharmacovigilance expertise.
• Significant knowledge of EU and FDA pharmacovigilance guidelines, GCP, and clinical research methodology.
• Strong leadership, problem-solving, negotiation, organization, planning, and communication skills.
• Scientific, clinical, and analytical expertise, including the ability to assess data and medical safety implications.
• Understanding of pharmacoepidemiology and the ability to critically evaluate observational studies; proficiency with Microsoft Word, Excel, and PowerPoint.

Nice to have

• Board certification.
• Oncology or immunology experience.
• CAR T experience.

Culture & Benefits

• People leadership focused on inclusion, talent development, and team empowerment.
• Medical, dental, vision, and life insurance plans.
• Paid time off and potential eligibility for an annual bonus.
• Potential eligibility for discretionary stock-based long-term incentives.